Ohio Life Insurance - Save up to 70% Off
See what plans you qualify for in just a few minutes
How Life Insurance Underwriters View GLP-1 Medications
GLP-1 receptor agonists — including Ozempic, Wegovy, Mounjaro, and Zepbound — are now among the most commonly prescribed medications in the United States. As of 2026, life insurance underwriters are encountering these drugs on applications daily, and their approach has evolved significantly from just a few years ago.
The good news: taking a GLP-1 medication does not automatically disqualify you from life insurance, and in many cases, it may actually work in your favor. Underwriters are increasingly outcome-focused. They care far less about the drug name itself and far more about your underlying health trajectory — whether your weight is dropping, your blood sugar is controlled, your blood pressure is improving, and whether obesity-related conditions are resolving.
Here's how most insurers approach GLP-1 use today:
| Applicant Profile | Likely Underwriting Outcome |
|---|---|
| Well-controlled diabetes, improved A1c, no complications | Standard or near-standard rates |
| Obesity with 6–12+ months of documented weight loss | Standard to mildly table-rated |
| Recent GLP-1 start (under 3 months), no track record | Possible postponement, re-apply in 6–12 months |
| High BMI with uncontrolled comorbidities | Table-rated or possible decline |
| Improved labs, resolved conditions (e.g., off CPAP) | Favorable — Preferred possible at progressive carriers |
The most progressive insurers now explicitly allow Preferred rate classes for applicants whose GLP-1 use has produced documented, sustained health improvements. More conservative carriers may still add a table rating or request a 6-month wait period. This is why carrier selection matters enormously.
If you're managing multiple health factors, it's also worth reading our guide on life insurance with pre-existing conditions to understand how insurers layer multiple risks together.
Ohio Life Insurance - Save up to 70% Off
See what plans you qualify for in just a few minutes
GLP-1 for Diabetes vs. Weight Loss: Key Underwriting Differences
The single biggest underwriting distinction for GLP-1 users is why the medication was prescribed. Insurers treat these two use cases quite differently.
If Your GLP-1 Is for Type 2 Diabetes (Ozempic, Mounjaro)
Underwriters focus heavily on your A1c level, the duration of your diagnosis, and the presence of any complications. A well-managed diabetic — stable A1c under 7%, no neuropathy, retinopathy, or kidney disease — can often qualify for Standard rates or close to it. GLP-1 use for diabetes is now seen as strong evidence of active medical management, which is viewed positively.
For a deeper look at how diabetes specifically affects your application, see our guide on life insurance for diabetics.
If Your GLP-1 Is for Weight Loss / Obesity (Wegovy, Zepbound)
For weight-loss use, the underwriter's primary question is: Has the risk actually improved? They want to see documented weight loss over at least 6 to 12 months, improvement in obesity-related conditions like high blood pressure or sleep apnea, and stable or continuing progress. A meaningful BMI reduction — say, from 41 to 33 — combined with improved lab results can shift an applicant from table-rated to standard.
If obesity is part of your profile, our dedicated guide on life insurance with obesity walks through exactly how BMI and build charts affect your rate class.
The Mortality Data That's Changing the Insurance Industry
Perhaps the most significant reason insurers are warming to GLP-1 users is the rapidly accumulating evidence that these drugs materially reduce mortality risk. Two major reinsurers — Munich Re and Swiss Re — have both published analyses that are reshaping how the industry thinks about these medications.
What the Data Shows
Munich Re's 2026 analysis examined GLP-1 users across both diabetic and non-diabetic populations and found lower all-cause mortality in GLP-1 users compared to non-users — in both groups. The mortality benefit was particularly pronounced in applicants under age 60, which is precisely the demographic that drives the most life insurance business. Their modeling suggests GLP-1 drugs could drive 0.2% to 0.5% annual mortality improvement in insured populations, realized over approximately 20 years.
Swiss Re has similarly projected that GLP-1 drugs could reduce U.S. mortality by up to 6.4% by 2045 by improving underlying risk factors like weight, blood sugar, and blood pressure at a population level.
Beyond cardiometabolic benefits, a large 2026 study published in the BMJ — using Veterans Affairs data — found that GLP-1 users showed:
| Risk Reduction | Magnitude |
|---|---|
| Developing any substance use disorder | ~14% lower |
| Alcohol use disorder | ~18% lower |
| Opioid-related events | ~25% lower |
| SUD-related deaths (existing SUD patients) | ~50% lower |
| Overdose risk | ~39% lower |
Additionally, the FDA confirmed in early 2026 that its review found no increased risk of suicidal ideation or behavior among GLP-1 users — removing a prior concern that some underwriters had flagged.
This data is shifting insurer attitudes from caution to cautious optimism. As Munich Re explicitly noted, if insurers fail to account for GLP-1 improvements in their underwriting, they risk overestimating mortality risk for these applicants — which can lead to overpriced coverage and adverse selection as healthier GLP-1 users shop elsewhere.
If you have other conditions that may interact with your application — such as high blood pressure or sleep apnea — those are also increasingly being viewed through the lens of whether a GLP-1 has helped bring them under control.
How to Disclose GLP-1 Use on a Life Insurance Application
Proper disclosure is non-negotiable. Omitting medications from your application — even those you consider "just for weight loss" — can give an insurer grounds to contest or cancel your policy later. Here's how to handle it correctly.
What You Must Disclose
GLP-1 medications should be disclosed anywhere the application asks about:
- Current prescription medications (list drug name, dose, frequency, and start date)
- Diabetes, prediabetes, or elevated blood sugar
- Obesity, weight loss treatment, or weight loss injections
- Cardiovascular risk factors or heart disease
- Related conditions such as high blood pressure, sleep apnea, or high cholesterol
How to Frame Your Disclosure
A strong, clear medication disclosure looks like this:
"Semaglutide (Ozempic) 1 mg weekly — for Type 2 diabetes diagnosed 2022. A1c 6.4% as of March 2026, no complications. Weight stable."
"Tirzepatide (Zepbound) 10 mg weekly — for obesity (BMI 37 → 31) with hypertension and sleep apnea — started September 2025. Lost 45 lbs. Blood pressure improved to 122/78."
If the application has a free-text section, use it to highlight positive trends: weight loss trajectory, resolved conditions, reduced medications, and clinical stability.
What Underwriters Will Ask About
Expect follow-up questions (directly or via your physician's records) covering:
Being transparent, consistent, and well-documented gives underwriters the information they need to justify a favorable rate class. Inconsistencies between your application and your medical records are a red flag — and insurers can access pharmacy records and physician statements to verify.
Since GLP-1 use often occurs alongside other manageable health conditions, it's worth reviewing how conditions like high blood pressure or pre-existing conditions generally are handled in the underwriting process.
Frequently Asked Questions
Will taking Ozempic or Wegovy automatically raise my life insurance rates?
No — GLP-1 medications do not automatically increase your premiums. In 2026, most life insurers view these drugs as a neutral to positive factor, depending on your health trajectory. If your weight is down, your labs have improved, and you have a documented track record on the medication, many carriers will rate you the same as — or better than — a similar applicant who is not being treated for obesity or diabetes at all.
Can I qualify for Preferred rates if I take a GLP-1 medication?
Yes, at progressive carriers. If you have documented weight loss, controlled blood sugar or blood pressure, and no significant complications, some insurers will place GLP-1 users in Preferred rate classes. The key is demonstrating sustained improvement with objective clinical data, not just the fact that you have a prescription. Working with an independent broker who knows which carriers are most favorable to GLP-1 users is the fastest path to a Preferred offer.
What if I take a GLP-1 medication for diabetes — does that make it harder to get life insurance?
Not necessarily. Taking a GLP-1 for Type 2 diabetes is now treated by most underwriters as evidence of active, responsible disease management. Insurers focus primarily on your A1c level, how long you've been diagnosed, and whether you have any complications. A well-controlled diabetic on a GLP-1 with a good A1c and no organ damage can often qualify for Standard rates. Learn more in our guide on life insurance for diabetics.
What happens if I stop taking my GLP-1 medication after I've been approved?
Your approved rate is locked in once your policy is issued — stopping your medication after approval generally does not affect your premium. However, if you apply for a new policy or increase your coverage later, underwriters will evaluate your current health status at that time. If you've regained weight or your health metrics have worsened since stopping the medication, it could affect your new application.
Do I have to disclose my GLP-1 medication if I'm buying a no-medical-exam life insurance policy?
Yes. Even simplified-issue or no-medical-exam policies require honest disclosure on the application. These policies rely on self-reported health information, and omitting a prescription medication is considered misrepresentation. If a claim is filed and the insurer discovers the omission during the contestability period (typically the first two years of the policy), they may deny the claim or rescind the coverage. Always disclose fully, regardless of the policy type.